CAR-T Cell Therapy for Mesothelioma: Penn huCART-meso Phase 1 (2026)

In May 2026, Molecular Therapy published the Phase 1 results of the University of Pennsylvania Abramson Cancer Center's huCART-meso program — autologous T cells engineered to carry a fully human anti-mesothelin chimeric antigen receptor (CAR) (Barber-Rotenberg, Haas, Aggarwal, O'Hara, Hexner, et al., PMID 41566776).^[1] The trial, registered as NCT03054298^[2], enrolled 20 patients with mesothelin-expressing cancers — 5 with malignant pleural mesothelioma (MPM), 14 with ovarian cancer, and 1 with lung adenocarcinoma — and tested intravenous, intrapleural, and intraperitoneal delivery of huCART-meso cells. It is the latest published step in Penn's roughly fifteen-year academic mesothelin CAR-T program and the first published trial of a fully human anti-mesothelin construct.

Why does "fully human" matter for a mesothelin CAR?

A chimeric antigen receptor combines an antibody-derived antigen-recognition module (a single-chain variable fragment, scFv) with intracellular signaling domains that activate the T cell when the scFv engages its target. The scFv is what tells the CAR-T cell where to go. The origin of the scFv — mouse, humanized, or fully human — determines how strongly the patient's immune system will recognize the engineered T cell itself as foreign.

Penn's earliest mesothelin CAR-T work used the murine SS1 anti-mesothelin scFv. Two publications from the Penn group document the immunogenicity problem that approach created. First, the 2013 Cancer Immunology Research paper by Maus, Haas, Beatty and colleagues reported anaphylaxis attributable to T cells expressing chimeric antigen receptors^[7] with murine scFvs in human recipients — an acute hypersensitivity response that limited safe repeat dosing. Second, the 2014 Cancer Immunology Research paper by Beatty, Haas, Maus and colleagues described an mRNA-engineered mesothelin CAR-T study^[8] that deliberately used transient mRNA (rather than stable lentiviral) expression of the CAR — in part to limit how long the murine sequence persisted in patients. By 2019, when Haas, Tanyi, O'Hara and colleagues published the Phase I lentiviral CART-meso study^[9] in Molecular Therapy, the program had moved to stable lentiviral expression but still reported in vivo persistence shortened by anti-CAR immune responses to the murine scFv.

The huCART-meso construct in the 2026 Phase 1 uses an scFv derived end-to-end from human antibody libraries — no murine framework, no humanization workaround. In principle, that removes the rodent epitopes that drove the earlier anti-CAR responses. The Phase 1 persistence data are consistent with the rationale: 80% of patients had detectable huCART-meso cells at Day 21, 5 of 20 still had detectable cells at 12 months, and one patient was followed with detectable cells beyond two years — well outside the persistence window the same investigators reported for earlier murine-scFv CART-meso products.^[1][9]

"Persistence is the part of the CAR-T story that doesn't make headlines but determines whether the therapy has any chance of working over time. The Penn group has been chasing this number for fifteen years — first with mRNA constructs to control on-target / off-tumor exposure, then with lentiviral CARs but a murine scFv that the body cleared too quickly, and now with a fully human construct that one patient maintained for more than two years. The Phase 1 doesn't show tumor shrinkage in the conventional sense, but it shows that the cell-engineering problem the program set out to solve is closer to solved than it has ever been."

— David Foster, Executive Director of Client Services, Danziger & De Llano

Why is mesothelin a CAR target in mesothelioma in the first place?

Mesothelin (encoded by the MSLN gene on chromosome 16p13.3) was first cloned and characterized by Kuan Chang and Ira Pastan in 1996 (Proceedings of the National Academy of Sciences USA^[6]) as a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. In normal tissues, mesothelin expression is restricted largely to the mesothelial cells lining the pleural, peritoneal, and pericardial cavities — a narrow normal-tissue footprint that has made it one of the most actively pursued targets in solid-tumor CAR-T development. A 2021 Biomedicines tissue microarray study of 12,679 tumors across 122 tumor types by Weidemann and colleagues^[10] showed very high mesothelin positivity in ovarian serous carcinoma and pancreatic ductal adenocarcinoma, and broad expression in epithelioid mesothelioma. Sarcomatoid mesothelioma typically does not stain meaningfully for mesothelin — and the Penn trial therefore excludes patients with predominantly sarcomatoid disease.^[2]

The combination of (1) high mesothelin density on epithelioid mesothelioma, (2) restricted normal-tissue distribution that mostly maps to surgically accessible mesothelial surfaces, and (3) the long-standing therapeutic gap in mesothelioma — where FDA-approved options for unresectable disease center on nivolumab + ipilimumab and pembrolizumab + chemotherapy regimens reviewed at the WikiMesothelioma Mesothelioma Immunotherapy page^[14] — makes mesothelin one of the most rationally chosen targets for solid-tumor adoptive cell therapy in 2026.

What did the Penn Phase 1 actually find?

All clinical data in this section trace directly to the Phase 1 publication (PMID 41566776) and the public ClinicalTrials.gov record for NCT03054298. Penn enrolled 20 patients across three administration routes — intravenous, intrapleural via indwelling pleural catheter, and intraperitoneal — with or without cyclophosphamide-based lymphodepletion. The Maximum Tolerated Dose was 1–3 × 10⁷ CAR⁺ cells/m². Higher-dose cohorts at 3 × 10⁸ CAR⁺ cells/m² were permanently closed during the study after dose-limiting toxicities.^[1][2]

The most common serious adverse event was cytokine release syndrome, occurring in 7 of 20 patients (35%). CRS in the Penn trial is graded against the 2019 ASTCT consensus criteria (Lee, Santomasso, Locke and colleagues, Biology of blood and marrow transplantation, 2019)^[11], which run from Grade 1 (fever ≥ 38 °C) to Grade 5 (death). Patient-level grading distributions and individual-cohort safety detail require full-text access; the published abstract reports the overall 35% incidence. The 35% any-grade CRS rate sits in the expected range for solid-tumor CAR-T programs administering cells systemically, and is in the same neighborhood as the 25% Grade ≥3 CRS reported in the NCI / TCR2 gavocabtagene autoleucel trial (Hassan, Butler, O'Cearbhaill and colleagues, Nature Medicine, 2023)^[12].

Best overall response in the Penn trial was stable disease in 12 of 20 patients (60%), with a maximum target-lesion reduction of 41% in a single best responder. No complete or partial responses were reported. Median overall survival was 26.1 weeks (approximately 6.5 months) and median progression-free survival was 12.3 weeks (approximately 3 months). The authors present the Phase 1 as establishing feasibility, safety, and preliminary efficacy of huCART-meso and as providing a rationale for future combination trials — for example, with checkpoint inhibitors, with regional delivery, or with combination cell-therapy strategies.

How does Penn huCART-meso fit into the broader mesothelin CAR-T landscape?

Mesothelin-targeted cell therapy in 2026 is an academic-and-biotech landscape with several distinct architectures and delivery strategies. The three most informative comparators for the Penn fully human IV-and-multi-route trial are:

• Memorial Sloan Kettering Cancer Center intrapleural CAR-T (NCT02414269):^[3] Phase I/II trial led by Prasad S. Adusumilli, MD, delivering a humanized scFv CAR with CD28 / CD3ζ signaling through an indwelling pleural catheter, with a subset of patients also receiving pembrolizumab. The architectural contrast with Penn is sharp — regional delivery vs. systemic, CD28-costimulated humanized vs. 4-1BB-costimulated fully human, and checkpoint-inhibitor combination as an integral design element vs. monotherapy in Penn's Phase 1.
• Gavocabtagene autoleucel / gavo-cel / TC-210 (NCT03907852):^[4] Multi-center Phase 1/2 trial of a T-cell-receptor-fusion-construct (TRuC) — an anti-mesothelin single-domain antibody fused to the endogenous TCR complex rather than a conventional CAR. The Phase 1 results published by Hassan and colleagues in Nature Medicine in 2023 (PMID 37501016)^[12] reported, in 30 evaluable patients (of 32 enrolled), a 20% objective response rate (13% confirmed), a 77% disease control rate, and a 6-month overall survival rate of 70% — and reported dose-limiting toxicities of grade 3 pneumonitis and a Grade 5 (fatal) bronchioalveolar hemorrhage at higher dose levels. The recommended Phase 2 dose was 1 × 10⁸ cells/m² after lymphodepletion; Grade ≥3 CRS occurred in 25% of all patients and in 15% at the RP2D. The pulmonary safety signal — alongside the Penn high-dose cohort closures — has shaped dose selection across the mesothelin cell-therapy field.
• NCI TNhYP218 CAR T cells (NCT06885697):^[5] NCI Phase 1 of a naïve / stem-cell-memory mesothelin CAR-T product for advanced mesothelin-positive solid tumors including epithelioid mesothelioma. The trial uses T-cell phenotype (rather than scFv engineering) as its lever for extending in vivo persistence — a different solution to the same persistence problem the Penn fully human construct addresses.

What does this mean for mesothelioma patients in 2026?

Mesothelin-targeted CAR-T is not an approved mesothelioma treatment in 2026 — all four programs above are investigational and delivered exclusively on registered clinical trials with strict eligibility criteria. For mesothelioma patients seeking trial information, the decision pathway generally begins with the patient's treating oncology team and proceeds through three filters:

1. Histology and subtype. Most mesothelin CAR-T programs prioritize epithelioid mesothelioma and exclude predominantly sarcomatoid disease; biphasic disease may be eligible if the epithelioid component exceeds a protocol-specified threshold.
2. Mesothelin expression on tumor tissue. Immunohistochemistry scoring on archival tumor tissue is generally required, with positivity thresholds that vary by protocol (NCT06885697, for example, requires ≥ 50% MSLN-positive tumor cells).
3. Performance status and travel logistics. Cell therapy requires a lymphodepleting chemotherapy regimen and ongoing monitoring at the trial center. For Penn huCART-meso, that means Philadelphia; for NCI TNhYP218, Bethesda; for MSKCC, New York; gavo-cel cohorts have included multiple US centers.

For broader context on where cell therapy sits relative to FDA-approved checkpoint-inhibitor regimens (nivolumab + ipilimumab; pembrolizumab + chemotherapy), see the WikiMesothelioma Mesothelioma Immunotherapy page. For trial-registry-level detail across the four programs above, including the full Penn Abramson lineage from the 2014 Beatty mRNA CART-meso paper through the 2026 huCART-meso publication, see the canonical Mesothelin CAR-T Therapy for Mesothelioma reference page. For practical guidance on coordinating cell therapy with broader mesothelioma treatment planning^[15], the firm's patient-support line is the simplest first call.

"Patients ask us about CAR-T more than any other experimental therapy because it sounds like the kind of immunological precision tool that ought to work in solid tumors. The honest answer in 2026 is that the field is still figuring out which patient, which construct, and which delivery route. The Penn Phase 1 doesn't change what we recommend to a newly diagnosed mesothelioma patient — first-line standards still apply — but it does change what we tell patients in trial-eligible windows: there is a fully human construct in the pipeline now that may finally have the persistence to combine with something else. Stay close to your treating team and to ClinicalTrials.gov."

— David Foster, Executive Director of Client Services, Danziger & De Llano

This article is a patient-oriented educational summary of published clinical-trial data. It is not medical advice. Treatment decisions, including decisions about trial enrollment, belong to a patient's oncology team. Mesothelin CAR-T is investigational and is not FDA-approved for mesothelioma as of 2026.